Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Cash from Financing Activities (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Cash from Financing Activities for 12 consecutive years, with $1000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Financing Activities fell 75.0% year-over-year to $1000.0, compared with a TTM value of $6000.0 through Sep 2025, down 33.33%, and an annual FY2024 reading of $9000.0, down 99.84% over the prior year.
  • Cash from Financing Activities was $1000.0 for Q3 2025 at Arcadia Biosciences, down from $5000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $22.0 million in Q1 2021 and bottomed at -$114000.0 in Q4 2021.
  • Average Cash from Financing Activities over 5 years is $2.7 million, with a median of $5000.0 recorded in 2024.
  • The sharpest move saw Cash from Financing Activities plummeted 101.47% in 2021, then skyrocketed 137525.0% in 2023.
  • Year by year, Cash from Financing Activities stood at -$114000.0 in 2021, then surged by 4060.53% to $4.5 million in 2022, then tumbled by 99.84% to $7000.0 in 2023, then crashed by 42.86% to $4000.0 in 2024, then crashed by 75.0% to $1000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for RKDA at $1000.0 in Q3 2025, $5000.0 in Q1 2025, and $4000.0 in Q3 2024.